

# Laurent Pessaint

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3413614/publications.pdf>

Version: 2024-02-01

28  
papers

6,812  
citations

331670  
21  
h-index

526287  
27  
g-index

43  
all docs

43  
docs citations

43  
times ranked

10615  
citing authors

| #  | ARTICLE                                                                                                                                                                                  | IF   | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1  | Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.                                                                                      | 27.8 | 995       |
| 2  | DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.                                                                                       | 12.6 | 978       |
| 3  | Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.                                              | 27.0 | 936       |
| 4  | SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.                                                                               | 12.6 | 789       |
| 5  | Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.                                                                             | 27.8 | 765       |
| 6  | REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. <i>Science</i> , 2020, 370, 1110-1115.                                                      | 12.6 | 476       |
| 7  | Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020, 26, 1694-1700.                                                              | 30.7 | 275       |
| 8  | A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. <i>Immunity</i> , 2020, 53, 724-732.e7.    | 14.3 | 267       |
| 9  | Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.                                                      | 12.6 | 244       |
| 10 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.    | 28.9 | 179       |
| 11 | Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.                                                        | 12.6 | 83        |
| 12 | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.                                                                         | 27.8 | 71        |
| 13 | Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.  | 28.9 | 64        |
| 14 | Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.                                                                           | 28.9 | 59        |
| 15 | mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.                                                               | 14.5 | 57        |
| 16 | Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, . | 12.4 | 56        |
| 17 | Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , 2021, 6, .                                                                         | 5.0  | 52        |
| 18 | Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.                                                                 | 28.9 | 49        |

| #  | ARTICLE                                                                                                                                                                                        | IF   | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.                                                                                 | 27.8 | 40        |
| 20 | Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.        | 12.4 | 32        |
| 21 | Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. <i>Cell Reports Medicine</i> , 2021, 2, 100420. | 6.5  | 28        |
| 22 | SARS-CoV-2 receptor binding domain displayed on HBsAg virusâ€“like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.                             | 10.3 | 27        |
| 23 | Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641. | 12.4 | 15        |
| 24 | Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 156.                                                                        | 6.0  | 15        |
| 25 | Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.                                           | 4.7  | 12        |
| 26 | One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. <i>Emerging Microbes and Infections</i> , 2021, 10, 2016-2029.        | 6.5  | 12        |
| 27 | Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery. <i>Frontiers in Virology</i> , 0, 2, .                               | 1.4  | 9         |
| 28 | Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JVI0159921.   | 3.4  | 5         |